Electronically filed 21 November 2006

Attorney Docket No. B45201

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

D'Hondt, et al.

21 November 2006

Serial No.:

10/088,632

Group Art Unit No.: 1648

Filed:

30 July 2002

Examiner:

Mosher, Mary

For:

Novel Composition

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Information Disclosure Statement Under 37 C.F.R. §1.97(c)

The attached list of citations is being submitted under the provisions of 37 C.F.R. §1.56 and §1.97 for consideration by the United States Patent and Trademark Office, prior to the granting of this patent. Their inclusion herein, however, should not be construed as an admission that any particular cited document is effective prior art or that it discloses or renders obvious any aspect of the claimed invention.

The documents cited herein are listed on the enclosed PTO Form 1449. A copy of each cited document is enclosed, except U.S. Patent documents, and those references which are already part of the filewrapper. This statement is being filed under the provisions of 37 C.F.R. §1.97(c), before the mailing date of a Final Office action or before the mailing date of a Notice of Allowance, along with authorization to charge the \$180.00 fee specified in 37 C.F.R. §1.17(p) to the Deposit Account No. 19-2570.

Please charge any additional fees under 37 C.F.R. §1.16 or §1.17 which may be required by this paper, or credit any overpayment, to the indicated Deposit Account.

Respectfully submitted,

Elizabeth J. Hecht

Attorney for Applicants Registration No. 41,824

GLAXOSMITHKLINE

Corporate Intellectual Property - UW2220

P.O. Box 1539

King of Prussia, PA 19406-0939

Phone (610) 270-5009 / Facsimile (610) 270-5090

Form PTO-		U.S. Department of Commerce Patent and Trademark Office			ATTY, DOCKET NO. B45201		SERIAL NO. 10/088,632			
INFO	RMATION DISCLOSE BY APPLICA		Т	APPLICANT D'Hondt, et al.						
(Use several sheets if necessary)				FILING DATE 30 July 2002						
	-,		ATEN	T DOCUMENTS			······			
Examiner Initial	Document Numbe	Document Number Date		Name	Class	Subclass	Filing Date If Appropriate			
		FOREIGN	N PAT	ENT DOCUMENTS						
	Document Numbe	r Date		Country	Class	Subclass	<u>Trans</u> Yes	slation I No		
	EP 0113 665	18-Jul-1984	EP				100	1,10		
	WO 95/22989	31-Aug-1995	PCT	•						
	J.A.M.A., 1957, Couch, et al., "Infectious Disea	Boger, et al., "Subcutaneous and Intradermal Vaccination with Asian Influenza Vaccine," J.A.M.A., 1957, 165(13):1687-1689. Couch, et al., "Improvement of Inactivated Influenza Virus Vaccines," The Journal of Infectious Diseases, 1997, 176:S38-S44. Hehme, N.W., "GSK's Pandemic Flu Vaccine Project: Evaluation of H2N2 and H9N2								
		Candidate Vaccines" GlaxoSmithKline Biologicals, Who Meeting on Development and Evaluation of Influenza Pandemic Vaccines, Geneva, 2005, pages 1-20.								
		Kistner, et al., "Development of a Mammalian Cell (Vero) Derived Candidate Influenza Virus Vaccine," Vaccine, 1998, 16(9/10):960-968.								
	Developments i	Kistner, et al., "Development of a Vero Cell-Derived Influenza Whole Virus Vaccine," Developments in Biological Standardization, 1999, 98:101-110.								
	_	La Montagne, et al., "Summary of Clinical Trials of Inactivated Influenza Vaccine," Reviews of Infectious Diseases, 1983, 5(4):723-736.								
		Lin, et al., "Safety and Immunogenicity of an Inactivated Adjuvanted Whole-Virion Influenza A (H5N1) Vaccine: A Phase I Randomised Controlled Trial," <i>The Lancet</i> , 2006, 368:991-997.								
	· · · · · · · · · · · · · · · · · · ·	Merten, et al., "Production of Influenza Virus in Cell Cultures for Vaccine Preparation," Advances in Experimental Medicine and Biology, 1996, 397:141-151.								
		Offit, et al., "Addressing Parents' Concerns: Do Vaccines Contain Harmful Preservatives, Adjuvants, Additives, or Residuals?" Pediatrics, 2003, 112(6):1394-1401.								
				odel Aluminum-Adj ce, 1995, 172:121-1		ntaining Vac	cines,"			
	Seeber, et al., "	Seeber, et al., "Predicting the Absorption of Proteins by Aluminum-Containing Adjuvants," Vaccine, 1991, 9:201-203.								
	Shirodkar, et al		-	nds Used as Adjuva	nts in Vac	cines," Phar	тасеиі	ical		

Serial No.: 10/088,632 Group Art Unit No.: 1648

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Stephenson, et al., "Development of Vaccines Against Influenza H5," The Lancet, 2006, 6:458-460.				
	Stephenson, I., "H5N1 Vaccines: How Prepared are we for a Pandemic?" <i>The Lancet</i> , 2006, 368:965-966. White, et al., Characterization of Aluminum-Containing Adjuvants," <i>Developmental Biology</i> 2000, 103:217-228. "Early Trial Show H5N1 Influenza Vaccine Safe and Effective in Humans at Low Doses," <i>The Lancet Press Release</i> , 2006.				
EXAMINER	DATE CONSIDERED				
·EXAMINER: I	nitial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in				

•EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copyof this form with next communication to applicant.

n:\ejh\applns\b cases\b45201\pto1449-3.doc